Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
// Filip Janku 1 , Philipp Angenendt 2 , Apostolia M. Tsimberidou 1 , Siqing Fu 1 Aung Naing 1 , Gerald S. Falchook 1 , David S. Hong 1 , Veronica R. Holley 1 , Goran Cabrilo 1 , Jennifer J. Wheler 1 , Sarina A. Piha-Paul 1 , Ralph G. Zinner 1 , Agop Y. Bedikian 3 , Michael J. Overman 4 , Bryan K. Kee 4 , Kevin B. Kim 3 , E. Scott Kopetz 4 , Rajyalakshmi Luthra 5 , Frank Diehl 2 , Funda Meric-Bernstam 1 , Razelle Kurzrock 1, 6 1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Sysmex Inostics GmbH, Hamburg, Germany 3 Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Molecular Diagnostic Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Moores Cancer Center, The University of California San Diego, La Jolla, CA, USA Correspondence to: Filip Janku, e-mail: fjanku@mdanderson.org Keywords: EGFR, BRAF, KRAS, PIK3CA, cell-free DNA Received: December 16, 2014 Accepted: February 11, 2015 Published: March 25, 2015 ABSTRACT Cell-free (cf) DNA in the plasma of cancer patients offers an easily obtainable source of biologic material for mutation analysis. Plasma samples from 157 patients with advanced cancers who progressed on systemic therapy were tested for 21 mutations in BRAF, EGFR, KRAS , and PIK3CA using the BEAMing method and results were compared to mutation analysis of archival tumor tissue from a CLIA-certified laboratory obtained as standard of care from diagnostic or therapeutic procedures. Results were concordant for archival tissue and plasma cfDNA in 91% cases for BRAF mutations (kappa = 0.75, 95% confidence interval [CI] 0.63 – 0.88), in 99% cases for EGFR mutations (kappa = 0.90, 95% CI 0.71– 1.00), in 83% cases for KRAS mutations (kappa = 0.67, 95% CI 0.54 – 0.80) and in 91% cases for PIK3CA mutations (kappa = 0.65, 95% CI 0.46 – 0.85). Patients ( n = 41) with > 1% of KRAS mutant cfDNA had a shorter median survival compared to 20 patients with </= 1% of KRAS mutant DNA (4.8 vs. 7.3 months, p = 0.008). Similarly, 67 patients with > 1% of mutant cfDNA ( BRAF, EGFR, KRAS , or PIK3CA ) had a shorter median survival compared to 33 patients with </= 1% of mutant cfDNA (5.5 vs. 9.8 months, p = 0.001), which was confirmed in multivariable analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“[32] In our study we did not perform serial plasma collections at multiple time points; however, we noticed several interesting observations.”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 2×
“[31] The second study, in patients who developed resistance to cetuximab or panitumumab, showed the emergence of KRAS amplification in one sample and acquisition of secondary KRAS mutations in 60% of the cases.”
BackgroundNon-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
Murtaza, M., Dawson, S.-J., Tsui, D. W. Y., Gale, D., Forshew, T., Piskorz, A. M., Parkinson, C., Chin, S.-F., Kingsbury, Z., Wong, A. S. C., et al. (2013) · Nature · doi:10.1038/nature12065 · Cited by 1,624 · cited 1×
“[29, 30] In addition, unlike tissue biopsies, obtaining samples of cfDNA is a noninvasive approach, with less risk to patients at a lower cost.”
Misale, S., Arena, S., Lamba, S., Siravegna, G., Lallo, A., Hobor, S., Russo, M., Buscarino, M., Lazzari, L., Sartore-Bianchi, A., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007947 · Cited by 263
Cited by
Goyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., et al. (2020) · Blood · doi:10.1182/blood.2019003507 · Cited by 416
Self-citationGoyal, G., Tazi, A., Go, R. S., Rech, K. L., Picarsic, J. L., Vassallo, R., Young, J. R., Cox, C. W., Van Laar, J., Hermiston, M. L., et al. (2022) · Blood · doi:10.1182/blood.2021014343 · Cited by 283
Chae, Y. K., Davis, A. A., Carneiro, B. A., Chandra, S., Mohindra, N., Kalyan, A., Kaplan, J., Matsangou, M., Pai, S., Costa, R., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11692 · Cited by 110
Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies
Abbou, S. D., Shulman, D. S., DuBois, S. G., & Crompton, B. D. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27595 · Cited by 72
Jia, J., Morse, M. A., Nagy, R. J., Lanman, R. B., & Strickler, J. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00305 · Cited by 17
Metadata
- Authors
- Janku, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., Piha-Paul, S. A., Zinner, R. G., Bedikian, A. Y., Overman, M. J., Kee, B. K., Kim, K. B., Kopetz, E. S., Luthra, R., Diehl, F., Meric-Bernstam, F., & Kurzrock, R.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-02-25
- Volume
- 6
- Issue
- 14
- Pages
- 12809-12821
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1778527589
- Cited by
- 94
- References
- 8
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. https://app.cochat.ai/papers/10.18632/oncotarget.3373
- The paper
- Janku, F., Angenendt, P., Tsimberidou, A. M., Fu, S., Naing, A., Falchook, G. S., Hong, D. S., Holley, V. R., Cabrilo, G., Wheler, J. J., Piha-Paul, S. A., Zinner, R. G., Bedikian, A. Y., Overman, M. J., Kee, B. K., Kim, K. B., Kopetz, E. S., Luthra, R., Diehl, F., . . . Kurzrock, R. (2015). Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. https://doi.org/10.18632/oncotarget.3373
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.